AR066668A1 - Composicion farmaceutica que comprende la combinacion de un agente anticonvulsivo y un agente antiviral - Google Patents
Composicion farmaceutica que comprende la combinacion de un agente anticonvulsivo y un agente antiviralInfo
- Publication number
- AR066668A1 AR066668A1 ARP080102159A ARP080102159A AR066668A1 AR 066668 A1 AR066668 A1 AR 066668A1 AR P080102159 A ARP080102159 A AR P080102159A AR P080102159 A ARP080102159 A AR P080102159A AR 066668 A1 AR066668 A1 AR 066668A1
- Authority
- AR
- Argentina
- Prior art keywords
- agent
- pharmaceutical composition
- combination
- convulsive
- gabapentin
- Prior art date
Links
- 239000001961 anticonvulsive agent Substances 0.000 title abstract 2
- 239000003443 antiviral agent Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 abstract 4
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 abstract 2
- 229960004150 aciclovir Drugs 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 229960002870 gabapentin Drugs 0.000 abstract 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 abstract 1
- 229940125681 anticonvulsant agent Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicacion 1: Composicion farmacéutica caracterizada por estar compuesta por la combinacion sinérgica de un agente anticonvulsivo, tal como lo es el principio activo: Gabapentina y un agente antiviral, tal como lo es el principio activoAciclovir, los cuales se encuentran presentes en la formulacion en un rango de concentracion de 300.0 mg. a 900.0 mg. para la Gabapentina y de 200.0 mg. a 800.0 mg. para el Aciclovir, además de excipientes farmacéuticamente aceptables; mismos que seencuentran formulados en una sola unidad de dosificacion para ser administrada por vía oral; la cual está indicada para la prevencion y/o tratamiento de la Neuralgia Post-herpética.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2007006093A MX2007006093A (es) | 2007-05-21 | 2007-05-21 | Composicion farmaceutica que comprende la combinacion de un agente anticonvulsivo y un agente antiviral. |
| PCT/MX2008/000061 WO2008143490A1 (es) | 2007-05-21 | 2008-05-19 | Composición farmacéutica que comprende la combinación de un agente anti convulsivo y un agente antiviral. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066668A1 true AR066668A1 (es) | 2009-09-02 |
Family
ID=40032120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102159A AR066668A1 (es) | 2007-05-21 | 2008-05-21 | Composicion farmaceutica que comprende la combinacion de un agente anticonvulsivo y un agente antiviral |
Country Status (7)
| Country | Link |
|---|---|
| AR (1) | AR066668A1 (es) |
| CL (1) | CL2008001476A1 (es) |
| CO (1) | CO6241103A2 (es) |
| MX (1) | MX2007006093A (es) |
| PE (1) | PE20090292A1 (es) |
| UY (1) | UY31095A1 (es) |
| WO (1) | WO2008143490A1 (es) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ508489A (en) * | 1998-07-09 | 2004-06-25 | Warner Lambert Co | Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles |
-
2007
- 2007-05-21 MX MX2007006093A patent/MX2007006093A/es not_active Application Discontinuation
-
2008
- 2008-05-19 UY UY31095A patent/UY31095A1/es not_active Application Discontinuation
- 2008-05-19 WO PCT/MX2008/000061 patent/WO2008143490A1/es active Application Filing
- 2008-05-20 CL CL200801476A patent/CL2008001476A1/es unknown
- 2008-05-20 PE PE2008000866A patent/PE20090292A1/es not_active Application Discontinuation
- 2008-05-21 AR ARP080102159A patent/AR066668A1/es unknown
-
2009
- 2009-11-11 CO CO09128266A patent/CO6241103A2/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CL2008001476A1 (es) | 2008-07-11 |
| MX2007006093A (es) | 2009-02-25 |
| UY31095A1 (es) | 2008-11-28 |
| WO2008143490A1 (es) | 2008-11-27 |
| CO6241103A2 (es) | 2011-01-20 |
| PE20090292A1 (es) | 2009-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| ES2553742T3 (es) | Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina | |
| AR068820A1 (es) | Composicion farmaceutica que comprende la combinacion de diversos agentes venotonicos y vasoprotectores para el tratamiento de la insuficiencia venosa cronica y uso | |
| AR048705A1 (es) | Composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii | |
| MX2009003372A (es) | Formas de dosificacion de pelicula no mucoadhesiva. | |
| BR9908121A (pt) | Forma galênica de liberação imediata e de liberação prolongada administrável por via oral compreendendo um agente estimulador de absorção e utilização deste agente estimulador de absorção | |
| BRPI0508833A (pt) | formulações galênicas de compostos orgánicos | |
| AR066666A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante | |
| CO6220945A2 (es) | Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma | |
| AR061233A1 (es) | Formulacion de liberacion prolongada de naltrexona | |
| AR065139A1 (es) | Medicamento para el tratamiento de la endometriosis | |
| PE20130147A1 (es) | Combinacion farmaceutica de teobromina y un agente antitusivo no opioide | |
| ES2526359T3 (es) | Formulación galénica oral que comprende ketorolaco y vitaminas del complejo B, en la que la vitamina B6 se encuentra en una capa externa separada del resto de principios activos | |
| CO2020001887A2 (es) | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático | |
| CO6270220A2 (es) | Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamotorio no esteroide y un agente inhibidor de la xantino oxidasa utiles para el control y el tratamiento de la gota artritis gotosa y enfermedades relacionadas | |
| MX2013001279A (es) | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. | |
| ECSP11010941A (es) | Composición farmacéutica para el uso en el tratamiento de infecciones de transmisión sexual | |
| AR066668A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente anticonvulsivo y un agente antiviral | |
| AR067320A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente antimicrobiano y un agente antioxidante para el tratamiento de infecciones urinarias | |
| AR066667A1 (es) | Composiciones farmaceuticas que comrenden la combinacion de un agente derivado hidrogenado de lipstatina y un agente inhibidor de hmg coa reductasa | |
| AR067861A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente anticonvulsivamente y un agente benzodiazepinico, indicada para el control y tratamiento de trastornos convulsivos y sindromes epilepticos | |
| AR048355A1 (es) | Asociacion entre un compuesto heterociclico y un agente antioxidante y las composiciones farmaceuticas que los contienen | |
| CO6260067A2 (es) | Composiciones farmaceutica que comprende la combinacion de acetacina metocarbamol y diacereina util en el tratamiento de la artritis y reumatoide t enfermedades relacionadas | |
| AR067465A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente benzodiazepinico | |
| AR063697A1 (es) | Dosis de biferunox para tratar esquizofrenia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |